[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-138093-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-138093-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","benefits-and-risks-of-testosterone-treatment-for-hypoactive-sexual-desire-disorder-in-women-a-critical-review","Benefits and Risks of Testosterone Treatment for Hypoactive Sexual Desire Disorder in Women - A Critical Review","","Reviewing decades before and after the introduction of phosphodiesterase type 5 inhibitors, the study evaluates androgen (testosterone) use for hypoactive sexual desire disorder in women by comparing publication eras and synthesizing available evidence. It searches multiple Latin-American and Caribbean and international databases with specified terms for female sexual dysfunction and testosterone, selecting articles in English, Portuguese, or Spanish. Results indicate a rise in testosterone-focused research after PDE5 inhibitors, while risks and benefits remain incompletely clarified, requiring further evidence for clinical decision-making.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/benefits-and-risks-of-testosterone-treatment-for-hypoactive-sexual-desire-disorder-in-women-a-critical-review/138093/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/benefits-and-risks-of-testosterone-treatment-for-hypoactive-sexual-desire-disorder-in-women-a-critical-review/138093.png","ImageObject",300,407,{"name":42,"@type":43},"Sarah ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-21","2026-08-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the review trying to determine about testosterone in women?","Question",{"text":63,"@type":64},"The review evaluates the use of androgens (testosterone) for lack of libido in women, comparing studies published before and after the advent of phosphodiesterase type 5 inhibitors, and analyzing benefits and risks.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the authors search for relevant studies?",{"text":68,"@type":64},"They searched multiple databases including Latin-American and Caribbean Health Sciences Literature, Cochrane Library, Excerpta Medica, SciELO, and Medline (PubMed) using defined terms related to female sexual dysfunction and testosterone.",{"name":70,"@type":61,"acceptedAnswer":71},"What conclusion does the review reach about the evidence quality?",{"text":72,"@type":64},"After PDE5 inhibitors, the number of studies on testosterone increased, but the risks and benefits of testosterone administration have not yet been fully clarified.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},138093,1787474437,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":80,"read_time":143},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","REVIEW  \nBenefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors  \nSandra Le´a Bonfim Reis,I Carmita H. N. AbdoII  \nI Faculdade de Medicina da Universidade de Sa˜o Paulo, Department of Pathophysiology, Sa˜o Paulo/SP, Brazil. II Faculdade de Medicina da Universidade de Sa˜o Paulo, Department of Psychiatry, Sa˜o Paulo/SP, Brazil.  \n| With advancing age, there is an increase in the complaints of a lack of a libido in women and erectile dysfunction in men. The efficacy of phosphodiesterase type 5 inhibitors, together with their minimal side effects and ease of administration, revolutionized the treatment of erectile dysfunction. For women, testosterone administration is the principal treatment for hypoactive sexual desire disorder. We sought to evaluate the use of androgens in the treatment of a lack of libido in women, comparing two periods, i.e., before and after the advent of the phosphodiesterase type 5 inhibitors. We also analyzed the risks and benefits of androgen administration. We searched the Latin-American and Caribbean Health Sciences Literature, Cochrane Library, Excerpta Medica, Scientific Electronic Library Online, and Medline (PubMed) databases using the search terms disfuna˜o sexual feminina/female sexual dysfunction, desejo sexual hipoativo/female hypoactive sexual desire disorder, testosterona/testosterone, terapia androgeˆnica em mulheres/androgen therapy in women, and sexualidade/sexuality as well as combinations thereof. We selected articles written in English, Portuguese, or Spanish.\u003Cbr>After the advent of phosphodiesterase type 5 inhibitors, there was a significant increase in the number of studies aimed at evaluating the use of testosterone in women with hypoactive sexual desire disorder. However,\u003Cbr>the risks and benefits of testosterone administration have yet to be clarified. KEYWORDS: Sexual Dysfunction; Physiological; Aging; Testosterone; Sexuality.\u003Cbr>Reis SL, Abdo CH. Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: a critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors. Clinics. 2014;69(4):294-303 . |\n| --- |\n| Received for publication on June 4, 2013; First review completed on June 27, 2013; Accepted for publication on September 10, 2013 |\n| E-mail: [sandra_lea@uol.com.br](sandra_lea@uol.com.br) |\n| Tel.: 55 17 3232-2801 |\n\n& INTRODUCTION  \nSince 1930, testosterone has been used to treat various gynecological problems such as uterine hemorrhage, myoma, dysmenorrhea, chronic mastitis, malignant endometrial tumors, and malignant breast tumors; the correlation between testosterone and the female libido was first reported by Loeser (in 1940) and was subsequently confirmed by Greenblatt et al. (in 1942) and Salmon et al.(in 1943) (1) . However, the sexual response is multifactorial and depends on psychological and social aspects; on the  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/by-nc/3.0/](http://creativecommons.org/licenses/by-nc/3.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nNo potential conflict of interest was reported.  \nDOI: 10.6061/clinics/2014(04)11  \neffects of hormones such as estrogen, prolactin, progesterone, and oxytocin; and on the effects of neurotransmitters and neuropeptides, including nitric oxide, dopamine, serotonin, and gamma-aminobutyric acid (1-10) . Therefore, it is difficult to determine the specific effects of testosterone on female hypoactive sexual desire disorder (HSDD) (10) .  \nIn the last decade, increasing attention has been given to the neurobiology of sexual function due to the ","cbCailZqYOgxhykS","https://ap.wps.com/l/cbCailZqYOgxhykS","pdf",674811,"English","# Review Overview\n## Study Rationale and Background\n## Search Strategy and Selection Criteria\n## Evidence After PDE5 Inhibitors\n## Risks and Benefits of Testosterone Therapy\n## Androgen Levels and Sexual Behavior in Aging Women","[{\"question\":\"What is the review trying to determine about testosterone in women?\",\"answer\":\"The review evaluates the use of androgens (testosterone) for lack of libido in women, comparing studies published before and after the advent of phosphodiesterase type 5 inhibitors, and analyzing benefits and risks.\"},{\"question\":\"How did the authors search for relevant studies?\",\"answer\":\"They searched multiple databases including Latin-American and Caribbean Health Sciences Literature, Cochrane Library, Excerpta Medica, SciELO, and Medline (PubMed) using defined terms related to female sexual dysfunction and testosterone.\"},{\"question\":\"What conclusion does the review reach about the evidence quality?\",\"answer\":\"After PDE5 inhibitors, the number of studies on testosterone increased, but the risks and benefits of testosterone administration have not yet been fully clarified.\"}]","Benefits and Risks of Testosterone Treatment for Hypoactive Sexual Desire Disorder in Women - A Critical Review | PDF",25]